Use of the HSP 110 Peptide Binding Protein for the Development of New Breast Cancer Vaccines
Abstract
Heat shock proteins have been examined in the last few years as anti-cancer vaccines. There are only a few major heat shock protein families in mammals, the most obvious being hsp28, hsp70, hsp90 and hspl 10. To date, hsp70 and hsp90 family members have been the primary candidates for preparation of anti-tumor vaccines. Hsp 110 has remained largely unstudied. Recently, hsp 110 has been initially cloned and characterized in this laboratory. We have hypothesize in our application, based largely on sequence data, that hsp 110 may be an excellent candidate for use as an anti-tumor, heat shock protein vaccine. The objective of our proposal was to test this hypothesis and examine peptides bound to hsp110. This first annual report describes the protocol for the purification of hspl 10 from tumors and normal tissue. Moreover, it describes the initial studies of purified hspl 10 in inhibiting the growth of a murine tumor model and in significantly extending survivability. These results demonstrate that hsp 110 can be used as an anti-cancer vaccine.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 1999
- Accession Number
- ADB259837
Entities
People
- John R. Subjeck
Organizations
- Health Research, Incorporated